Trelegy brought Royalty Pharma an extra $12.4 million in royalty receipts during the three months ended March 31. GSK’s inhaler delivered a disclosed product contribution, helped by volume growth, patient demand, broader use of triple therapy, and market-share gains.
That sounds like a straightforward growth story. Revenue rose 3.5% to $630.6 million, and operating income jumped 31.8% to $563.0 million. The less straightforward part is what happened below that line: net income increased just 2.2%, diluted EPS stayed at $0.67, and cash fell from $938.9 million to $586.4 million.
The gap starts with Royalty Pharma’s accounting for expected royalty cash flows. Its operating margin rose to 89.3% from 70.1%, a striking move for a business whose revenue growth stayed in the low single digits. Management says the change included provision income tied to higher sales forecasts for Evrysdi, Tysabri, and Xtandi, partly offset by an Adstiladrin charge.
The company describes that provision as a non-cash adjustment to the expected cash flows and credit losses attached to its financial royalty assets. In plain English, the reported operating profit got a lift from revised estimates of future royalty collections, not only from royalties collected during the period.
Management’s explanation is unusually specific:
"We recorded provision income for changes in expected cash flows primarily related to Evrysdi, Tysabri and Xtandi due to increases in sell-side equity research analysts’ consensus sales forecasts, partially offset by provision expense related to Adstiladrin due to changes in sales forecasts."
Royalty Pharma, 10-Q, May 6, 2026
That helps explain why operating income moved so much faster than revenue. It also leaves net income with a different shape, because Royalty Pharma recorded investment losses and paid more to finance the portfolio.
"Other expense, net of $22.8 million in the first quarter of 2026 was primarily comprised of $20.2 million of losses on equity securities and $6.7 million of losses on available for sale debt securities primarily driven by the changes in fair value of the Cytokinetics Funding Arrangements, partially offset by $6.2 million of interest income earned on cash and cash equivalents."
Royalty Pharma, 10-Q, May 6, 2026
The result is a business that showed an 89.3% operating margin but a 46.7% net margin, down slightly from 47.3%. Stock compensation also rose 66.7% to $122.3 million, while research and development spending fell 21.2% to $39.8 million. The filing does not tie those two movements into one operating explanation.
Debt adds another recurring claim on the economics. Interest expense rose 43.6%, or $28.5 million, after Royalty Pharma issued $2.0 billion of senior unsecured notes and assumed a $380 million term loan as part of its internalization. At the latest close, shares were up 0.5% at $57.47, after a 54.9% gain over 12 months.
The next quarterly report from Royalty Pharma will provide the factual comparison that matters here: whether provision income or expense from revised royalty forecasts continues to reshape operating profit, alongside the cash balance and interest bill.
The tension is simple: Royalty Pharma is collecting growing royalties, but its reported profit is moving on estimates, investments, and financing as much as on sales.